THE LUSTGARTEN FOUNDATION IS BOLDY LEADING THE WAY THROUGH HOPE AND INNOVATION, TURNING FEAR INTO ACTION THROUGH EDUCATION AND EMPOWERMENT, AND ADVANCING THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. SEE SCHEDULE OTHE LUSTGARTEN FOUNDATION IS BOLDY LEADING THE WAY THROUGH HOPE AND INNOVATION, TURNING FEAR INTO ACTION THROUGH EDUCATION AND EMPOWERMENT, AND ADVANCING THE BEST SCIENCE TO TRANSFORM PANCREATIC CANCER INTO A CURABLE DISEASE. THE FOUNDATION FOCUSES ON TRANSLATING OUR UNDERSTANDING OF THE UNDERLYING BIOLOGY OF PANCREATIC CANCER INTO CLINICAL APPLICATIONS TO CHANGE, EXTEND, AND ULTIMATELY SAVE PATIENTS' LIVES. IN FY24, THE FOUNDATION AWARDED $21.8 MILLION TO FUEL CUTTING-EDGE PANCREATIC CANCER RESEARCH, INCLUDING 10 NEW GRANTS TO RESEARCHERS AT SEVEN LEADING INSTITUTIONS. RESEARCH EFFORTS ARE CONCENTRATED ON THREE KEY PILLARS: EARLY DETECTION AND INTERCEPTION, DRUG DEVELOPMENT, AND PERSONALIZED MEDICINE.
Executive compensation, broken down
Form 990 · Schedule J · 8 reported individuals · Filing year 2023
| Base salary | Bonus | Other compensation | Benefits | Executive compensation | |
|---|---|---|---|---|---|
SVP Technology & Business Intelligence senior vice president $322k | |||||
VP Research vice president $311k | |||||
Head Clinical Research & Development highest compensated employee $198k | |||||
Director External & Community Relations highest compensated employee $194k | |||||
Plus 19 unpaid individuals.
Up 13%
from 2022
From $460k in 2022 to $521k in 2023.
Among peers
Revenue and top compensation, plotted against similar organizations. This organization is highlighted in cyan.
Compare any role, sector, or revenue band
Build your own benchmark from millions of reported positions.